Lomonitinib - Eilean Therapeutics
Alternative Names: ZE-460134Latest Information Update: 13 Jun 2024
At a glance
- Originator Eilean Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; IRAK4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia
Most Recent Events
- 10 Jun 2024 Eilean Therapeutics approves IND application for Lomonitinib in Acute myeloid leukemia
- 19 Apr 2024 Eilean Therapeutics plans a phase I trial for Acute myeloid leukemia (Second line therapy or greater) in Australia (PO) (NCT06366789)
- 04 Apr 2024 Eilean Therapeutics receives clearance from Human Research Ethics Committee in Australia for lomonitinib in Acute myeloid leukemia